Merck is halting shipments of a top-selling vaccine to China to help a key local supplier reduce excess inventory, hurting sales forecasts for one of its blockbuster medicines.
In results published on Tuesday, the pharmaceutical group forecast full-year sales of $64.1bn-$65.6bn in 2025, broadly flat compared with $64.1bn of sales last year and less than consensus expectations of $67.3bn.
Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus, which is linked with cervical cancer.
您已阅读28%（628字），剩余72%（1587字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。